Pain management · 2024
Comparison of responders and nonresponders with knee osteoarthritis after transcranial direct current stimulation.
Клиническое исследованиеСравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Park Juyoung, Tong Heling, Kang Yixin, Miao Hongyu, Lin Lifeng, Fox Rina S, Telkes Ilknur, Martorella Geraldine, Ahn Hyochol
Аннотация
AIM: The study compared responders and nonresponders to transcranial direct current stimulation (tDCS) regarding clinical pain outcomes in knee osteoarthritis (OA) patients.
PATIENTS AND METHODS/MATERIALS: Sixty participants received home-based active tDCS, and clinical pain outcomes were compared between responders and nonresponders.
RESULTS: Latent class growth analyses classified 41 participants as responders and 19 as nonresponders. Responders showed significantly greater decreases in pain intensity from baseline to post intervention than nonresponders (p < .001). Participants with higher BMI (p = .02) and weight (p = .005) were more likely to respond, while no significant sociodemographic differences were found.
CONCLUSIONS: Identifying characteristics of nonresponsive tDCS subgroups can tailor treatments for each group.
CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT04016272.
PATIENTS AND METHODS/MATERIALS: Sixty participants received home-based active tDCS, and clinical pain outcomes were compared between responders and nonresponders.
RESULTS: Latent class growth analyses classified 41 participants as responders and 19 as nonresponders. Responders showed significantly greater decreases in pain intensity from baseline to post intervention than nonresponders (p < .001). Participants with higher BMI (p = .02) and weight (p = .005) were more likely to respond, while no significant sociodemographic differences were found.
CONCLUSIONS: Identifying characteristics of nonresponsive tDCS subgroups can tailor treatments for each group.
CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT04016272.